-
41.发明申请公开(公告)号：US20170253633A1
公开(公告)日：2017-09-07
申请号：US15445461
申请日：2017-02-28
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , C07K16/18 , G01N33/68 , A61K35/17 , A61K39/00 , C12N15/115 , C07K7/06 , C07K14/725
CPC classification number: C07K7/08 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K2319/00 , C12N15/115 , C12N2310/16 , G01N33/6893 , G01N2800/52
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20160289296A1
公开(公告)日：2016-10-06
申请号：US15082920
申请日：2016-03-28
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
CPC classification number: A61K39/0011 , A61K35/17 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G06F19/20
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
43.发明公开公开(公告)号：US20230340046A1
公开(公告)日：2023-10-26
申请号：US18314878
申请日：2023-05-10
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/001102 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/2818 , C07K16/30 , C12N5/0638 , C12N15/1062 , C12N15/115 , G01N33/57492 , A61K35/17 , C07K7/06 , C07K14/5434 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2501/50 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
44.发明公开公开(公告)号：US20230287069A1
公开(公告)日：2023-09-14
申请号：US17819470
申请日：2022-08-12
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , G01N33/574 , C07K16/30 , C12N5/0783 , A61K39/00 , C07K14/725 , A61P35/00 , C12N15/10 , C07K7/06 , C07K14/54 , C07K14/74 , C12N15/115 , C07K16/28
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , A61K39/001102 , A61P35/00 , C07K7/06 , C07K14/5434 , C07K14/7051 , C07K14/70539 , C07K16/30 , C07K16/2818 , C12N5/0638 , C12N15/115 , C12N15/1062 , G01N33/57492 , A61K38/00 , A61K2039/572 , C07K2319/00 , C12N2501/50
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
45.发明公开公开(公告)号：US20230279066A1
公开(公告)日：2023-09-07
申请号：US18297076
申请日：2023-04-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/001102 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/2818 , C07K16/30 , C12N5/0638 , C12N15/1062 , C12N15/115 , G01N33/57492 , A61K35/17 , C07K7/06 , C07K14/5434 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2501/50 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
46.发明公开公开(公告)号：US20230242604A1
公开(公告)日：2023-08-03
申请号：US18170154
申请日：2023-02-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12Q1/6886 , G16B25/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230116279A1
公开(公告)日：2023-04-13
申请号：US17929347
申请日：2022-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230094286A1
公开(公告)日：2023-03-30
申请号：US17929344
申请日：2022-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230035702A1
公开(公告)日：2023-02-02
申请号：US17930891
申请日：2022-09-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K7/06 , C07K14/725 , A61K35/17 , C07K14/74 , C07K16/30 , C07K16/28 , C12N15/10 , A61K39/00 , C07K14/54 , G01N33/574 , C12N5/0783 , C12N15/115 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20220363729A1
公开(公告)日：2022-11-17
申请号：US17860803
申请日：2022-07-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , A61K39/00 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
236
records
(took 0.019 seconds)
